Triple agonist
What a GLP-1 receptor agonist actually does: which receptors it reaches, how it slows gastric emptying, and the satiety pathway it runs through.
What is Triple agonist?
A peptide activating three metabolic receptors at once, typically GIP, GLP-1 and glucagon.
Retatrutide is the first in clinical development for weight loss, with the glucagon arm hypothesized to add energy expenditure on top of appetite suppression. ⛔ None is approved, which does not stop them being sold.
Retatrutide: triple-agonist evidence →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Triple agonist comes up on this site
On GLP Watchdog, Triple agonist comes up in 1 research article and 2 FDA warning letters. Browse the FDA warning letters.
Research that discusses it
Connected terms
Other terms under Mechanism
- GLP-1 receptor
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Amylin
- GLP-1 tachyphylaxis
- Non-peptide GLP-1 agonist
- A1C (glycated hemoglobin)
- MASH / MASLD
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Where the evidence lives
- Retatrutide: triple-agonist evidence
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers